Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Resistance studies with Streptococcus pneumoniae using an in vitro dynamic model: amoxicillin versus azithromycin at clinical exposures.

Golikova MV, Strukova EN, Portnoy YA, Dovzhenko SA, Kobrin MB, Zinner SH, Firsov AA.

J Chemother. 2019 Jun 8:1-9. doi: 10.1080/1120009X.2019.1623361. [Epub ahead of print]

PMID:
31179907
2.

Concentration-dependent enrichment of resistant Enterococcus faecium exposed to linezolid in an in vitro dynamic model.

Alieva KN, Golikova MV, Portnoy YA, Dovzhenko SA, Kobrin MB, Zinner SH, Firsov AA.

J Chemother. 2018 Oct - Dec;30(6-8):364-370. doi: 10.1080/1120009X.2018.1533267.

PMID:
30663551
3.

Predicting antibiotic combination effects on the selection of resistant Staphylococcus aureus: In vitro model studies with linezolid and gentamicin.

Zinner SH, Golikova MV, Strukova EN, Portnoy YA, Firsov AA.

Int J Antimicrob Agents. 2018 Dec;52(6):854-860. doi: 10.1016/j.ijantimicag.2018.09.005. Epub 2018 Sep 17.

PMID:
30236953
4.

Time inside the mutant selection window as a predictor of staphylococcal resistance to linezolid.

Alieva KN, Strukova EN, Golikova MV, Portnoy YA, Zinner SH, Firsov AA.

J Antibiot (Tokyo). 2018 May;71(5):514-521. doi: 10.1038/s41429-017-0016-9. Epub 2018 Jan 18.

PMID:
29348530
5.

Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to linezolid in an in vitro dynamic model.

Firsov AA, Alieva KN, Strukova EN, Golikova MV, Portnoy YA, Dovzhenko SA, Kobrin MB, Romanov AV, Edelstein MV, Zinner SH.

J Antimicrob Chemother. 2017 Nov 1;72(11):3100-3107. doi: 10.1093/jac/dkx249.

PMID:
28981793
6.

Species differences in ciprofloxacin resistance among Gram-negative bacteria: can "anti-mutant" ratios of the area under the concentration-time curve to the MIC be achieved clinically?

Strukova EN, Portnoy YA, Zinner SH, Firsov AA.

J Chemother. 2017 Dec;29(6):351-357. doi: 10.1080/1120009X.2017.1335980. Epub 2017 Jun 6.

PMID:
28587559
7.

Predicting effects of antibiotic combinations using MICs determined at pharmacokinetically derived concentration ratios: in vitro model studies with linezolid- and rifampicin-exposed Staphylococcus aureus.

Golikova MV, Strukova EN, Portnoy YA, Dovzhenko SA, Kobrin MB, Zinner SH, Firsov AA.

J Chemother. 2017 Oct;29(5):267-273. doi: 10.1080/1120009X.2017.1281093. Epub 2017 Feb 13.

PMID:
28192070
8.

Synthesis and Antibacterial Activity of Quaternary Ammonium 4-Deoxypyridoxine Derivatives.

Shtyrlin NV, Sapozhnikov SV, Galiullina AS, Kayumov AR, Bondar OV, Mirchink EP, Isakova EB, Firsov AA, Balakin KV, Shtyrlin YG.

Biomed Res Int. 2016;2016:3864193. Epub 2016 Oct 5.

9.

Pharmacokinetically-based prediction of the effects of antibiotic combinations on resistant Staphylococcus aureus mutants: in vitro model studies with linezolid and rifampicin.

Firsov AA, Golikova MV, Strukova EN, Portnoy YA, Dovzhenko SA, Kobrin MB, Zinner SH.

J Chemother. 2017 Aug;29(4):220-226. doi: 10.1080/1120009X.2016.1245174. Epub 2016 Oct 17.

PMID:
27748167
10.

Concentration-Dependent Enrichment of Linezolid-Resistant Staphylococcus aureus in an in vitro Dynamic Model.

Alieva KN, Strukova EN, Golikova MV, Portnoy YA, Firsov AA.

Antibiot Khimioter. 2016;61(9-10):28-32. English, Russian.

PMID:
29539248
11.

Searching for the Optimal Predictor of Ciprofloxacin Resistance in Klebsiella pneumoniae by Using In Vitro Dynamic Models.

Strukova EN, Portnoy YA, Romanov AV, Edelstein MV, Zinner SH, Firsov AA.

Antimicrob Agents Chemother. 2015 Dec 7;60(3):1208-15. doi: 10.1128/AAC.02334-15.

12.

Predictors of bacterial resistance using in vitro dynamic models: area under the concentration-time curve related to either the minimum inhibitory or mutant prevention antibiotic concentration.

Strukova EN, Portnoy YA, Zinner SH, Firsov AA.

J Antimicrob Chemother. 2016 Mar;71(3):678-84. doi: 10.1093/jac/dkv387. Epub 2015 Nov 30.

PMID:
26626718
13.

Bacterial antibiotic resistance studies using in vitro dynamic models: Population analysis vs. susceptibility testing as endpoints of mutant enrichment.

Firsov AA, Strukova EN, Portnoy YA, Shlykova DS, Zinner SH.

Int J Antimicrob Agents. 2015 Sep;46(3):313-8. doi: 10.1016/j.ijantimicag.2015.06.007. Epub 2015 Jul 16.

PMID:
26297633
14.

[PK/PD Modeling as a Tool for Predicting Bacterial Resistance to Antibiotics: Alternative Analyses of Experimental Data].

Golikova MV, Strukova EN, Portnoy YA, Firsov AA.

Antibiot Khimioter. 2015;60(9-10):12-6. Russian.

PMID:
27141633
15.

In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus.

Firsov AA, Golikova MV, Strukova EN, Portnoy YA, Romanov AV, Edelstein MV, Zinner SH.

Antimicrob Agents Chemother. 2015 Feb;59(2):1014-9. doi: 10.1128/AAC.04214-14. Epub 2014 Dec 1.

16.

Predicting bacterial resistance using the time inside the mutant selection window: possibilities and limitations.

Firsov AA, Portnoy YA, Strukova EN, Shlykova DS, Zinner SH.

Int J Antimicrob Agents. 2014 Oct;44(4):301-5. doi: 10.1016/j.ijantimicag.2014.06.013. Epub 2014 Jul 27.

PMID:
25218155
17.

Bacterial resistance studies using in vitro dynamic models: the predictive power of the mutant prevention and minimum inhibitory antibiotic concentrations.

Firsov AA, Strukova EN, Shlykova DS, Portnoy YA, Kozyreva VK, Edelstein MV, Dovzhenko SA, Kobrin MB, Zinner SH.

Antimicrob Agents Chemother. 2013 Oct;57(10):4956-62. doi: 10.1128/AAC.00578-13. Epub 2013 Jul 29.

18.

Concentration-resistance relationships with Pseudomonas aeruginosa exposed to doripenem and ciprofloxacin in an in vitro model.

Zinner SH, Gilbert D, Greer K, Portnoy YA, Firsov AA.

J Antimicrob Chemother. 2013 Apr;68(4):881-7. doi: 10.1093/jac/dks463. Epub 2012 Nov 21.

PMID:
23175594
19.

Comparative pharmacodynamics and antimutant potentials of doripenem and imipenem with ciprofloxacin-resistant Pseudomonas aeruginosa in an in vitro model.

Firsov AA, Gilbert D, Greer K, Portnoy YA, Zinner SH.

Antimicrob Agents Chemother. 2012 Mar;56(3):1223-8. doi: 10.1128/AAC.05964-11. Epub 2011 Dec 27.

20.

The antistaphylococcal pharmacodynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model.

Smirnova MV, Strukova EN, Portnoy YA, Dovzhenko SA, Kobrin MB, Zinner SH, Firsov AA.

J Chemother. 2011 Jun;23(3):140-4.

PMID:
21742582
21.

[Pharmacokinetics of n-(5-oxynicotinoyl)-L-glutamic acid calcium salt upon bolus administration in rats and rabbits: interspecies extrapolation].

Firsov AA, Portnoń≠ IuA, Dovzhenko SA, Kobrin MB, Kiselev AV, Stovbun SV, Dolgova GV, Pomerantseva TIa.

Eksp Klin Farmakol. 2010 Dec;73(12):31-5. Russian.

PMID:
21395015
22.

The impact of duration of antibiotic exposure on bacterial resistance predictions using in vitro dynamic models.

Smirnova MV, Vostrov SN, Strukova EV, Dovzhenko SA, Kobrin MB, Portnoy YA, Zinner SH, Firsov AA.

J Antimicrob Chemother. 2009 Oct;64(4):815-20. doi: 10.1093/jac/dkp287. Epub 2009 Aug 11.

PMID:
19671586
23.

Linezolid pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.

Strukova EN, Smirnova MV, Vostrov SN, Lubenko IY, Firsov AA, Zinner SH, Portnoy YA.

Int J Antimicrob Agents. 2009 Mar;33(3):251-4. doi: 10.1016/j.ijantimicag.2008.09.006. Epub 2008 Dec 17.

PMID:
19095420
24.

Enrichment of resistant Staphylococcus aureus at ciprofloxacin concentrations simulated within the mutant selection window: bolus versus continuous infusion.

Firsov AA, Smirnova MV, Strukova EN, Vostrov SN, Portnoy YA, Zinner SH.

Int J Antimicrob Agents. 2008 Dec;32(6):488-93. doi: 10.1016/j.ijantimicag.2008.06.031. Epub 2008 Sep 14.

PMID:
18790614
25.

Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model.

Lubenko IY, Strukova EV, Smirnova MV, Vostrov SN, Portnoy YA, Zinner SH, Firsov AA.

J Antimicrob Chemother. 2008 Nov;62(5):1065-9. doi: 10.1093/jac/dkn288. Epub 2008 Jul 17.

PMID:
18635520
26.

Enrichment of fluoroquinolone-resistant Staphylococcus aureus: oscillating ciprofloxacin concentrations simulated at the upper and lower portions of the mutant selection window.

Firsov AA, Lubenko IY, Smirnova MV, Strukova EN, Zinner SH.

Antimicrob Agents Chemother. 2008 Jun;52(6):1924-8. doi: 10.1128/AAC.01371-07. Epub 2008 Mar 31.

27.

Selection of linezolid-resistant Enterococcus faecium in an in vitro dynamic model: protective effect of doxycycline.

Zinner SH, Gilbert D, Lubenko IY, Greer K, Firsov AA.

J Antimicrob Chemother. 2008 Mar;61(3):629-35. doi: 10.1093/jac/dkm542. Epub 2008 Feb 1.

PMID:
18245198
28.
29.

Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model.

Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH.

J Antimicrob Chemother. 2006 Dec;58(6):1185-92. Epub 2006 Oct 5.

PMID:
17028094
30.

Nanofabricated media with negative permeability at visible frequencies.

Grigorenko AN, Geim AK, Gleeson HF, Zhang Y, Firsov AA, Khrushchev IY, Petrovic J.

Nature. 2005 Nov 17;438(7066):335-8.

PMID:
16292306
31.

Two-dimensional gas of massless Dirac fermions in graphene.

Novoselov KS, Geim AK, Morozov SV, Jiang D, Katsnelson MI, Grigorieva IV, Dubonos SV, Firsov AA.

Nature. 2005 Nov 10;438(7065):197-200.

PMID:
16281030
32.
33.
34.

Comparative pharmacodynamics of the new fluoroquinolone ABT492 and levofloxacin with Streptococcus pneumoniae in an in vitro dynamic model.

Firsov AA, Alferova IV, Smirnova MV, Lubenko IY, Portnoy YA, Zinner SH.

Int J Antimicrob Agents. 2005 May;25(5):409-13.

PMID:
15848296
35.

Electric field effect in atomically thin carbon films.

Novoselov KS, Geim AK, Morozov SV, Jiang D, Zhang Y, Dubonos SV, Grigorieva IV, Firsov AA.

Science. 2004 Oct 22;306(5696):666-9.

36.

Comparative pharmacodynamics of the new fluoroquinolone ABT492 and ciprofloxacin with Escherichia coli and Pseudomonas aeruginosa in an in vitro dynamic model.

Zinner SH, Vostrov SN, Alferova IV, Lubenko IY, Portnoy YA, Firsov AA.

Int J Antimicrob Agents. 2004 Aug;24(2):173-7.

PMID:
15288317
37.

ABT492 and levofloxacin: comparison of their pharmacodynamics and their abilities to prevent the selection of resistant Staphylococcus aureus in an in vitro dynamic model.

Firsov AA, Vostrov SN, Lubenko IY, Arzamastsev AP, Portnoy YA, Zinner SH.

J Antimicrob Chemother. 2004 Jul;54(1):178-86. Epub 2004 Jun 9.

PMID:
15190041
38.
39.
40.
41.

In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.

Firsov AA, Vostrov SN, Lubenko IY, Drlica K, Portnoy YA, Zinner SH.

Antimicrob Agents Chemother. 2003 May;47(5):1604-13.

42.

Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters.

Firsov AA, Zinner SH, Lubenko IY, Portnoy YA, Vostrov SN.

Chemotherapy. 2002;48(6):275-9.

PMID:
12673102
43.

Species-independent pharmacodynamics of gemifloxacin and ciprofloxacin with Haemophilus influenzae and Moraxella catarrhalis in an in vitro dynamic model.

Portnoy YA, Vostrov SN, Lubenko IY, Zinner SH, Firsov AA.

Int J Antimicrob Agents. 2002 Sep;20(3):201-5.

PMID:
12385699
44.

AUC/MIC relationships to different endpoints of the antimicrobial effect: multiple-dose in vitro simulations with moxifloxacin and levofloxacin.

Firsov AA, Zinner SH, Vostrov SN, Portnoy YA, Lubenko IY.

J Antimicrob Chemother. 2002 Oct;50(4):533-9.

PMID:
12356798
45.
46.

Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils.

Firsov AA, Zinner SH, Vostrov SN, Kononenko OV, Portnoy YA, Shustova LV, Kadenatsi IB.

J Antimicrob Chemother. 2002 Jan;49(1):113-9.

PMID:
11751774
47.

The pharmacodynamics of gatifloxacin and ciprofloxacin for pneumococci in an in vitro dynamic model: prediction of equiefficient doses.

Zinner SH, Firsov AA, Gilbert D, Simmons K, Lubenko IY.

J Antimicrob Chemother. 2001 Dec;48(6):821-6.

PMID:
11733466
48.

Comparative anti-staphylococcal effects of gemifloxacin and trovafloxacin in an in vitro dynamic model in terms of AUC/MIC and dose relationships.

Zinner SH, Vostrov SN, Lubenko IY, Portnoy YA, Cornaglia G, Firsov AA.

Diagn Microbiol Infect Dis. 2001 Aug;40(4):167-71.

PMID:
11576789
49.

[Importance of pharmacokinetic studies for antibiotic therapy in children with pneumonia].

Kaganov SIu, Sorokina EV, Firsov AA.

Antibiot Khimioter. 2000;45(11):31-2. Russian. No abstract available.

PMID:
11210302
50.

Supplemental Content

Loading ...
Support Center